Payment overview · 2025
General Payments
$130.76
7 reported records · 5 companies
Healthcare provider profile · identity verified
Justin Walker, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MIAMI, OK · NPI 1356781462
Verified facts
What the public records show
CMS Open Payments records show Justin Walker, D.O. received $130.76 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 45.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.85 | 45.0% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.38 | 16.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.86 | 15.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.20 | 11.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.47 | 11.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $130.76 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $58.85 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 503 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 363 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 94 |
| Gabapentin | Gabapentin | 262 | 85 |
| Lisinopril | Lisinopril | 260 | 77 |
| Losartan Potassium | Losartan Potassium | 226 | 67 |
| Omeprazole | Omeprazole | 223 | 63 |
| Pregabalin | Pregabalin | 213 | 39 |
| Montelukast Sodium | Montelukast Sodium | 212 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 199 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 184 | 71 |
| Carvedilol | Carvedilol | 184 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 183 | 31 |
| Alprazolam | Alprazolam | 166 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 152 | 40 |
| Metformin Hcl | Metformin Hcl | 152 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 148 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 143 | 33 |
| Meloxicam | Meloxicam | 143 | 44 |
| Ozempic | Semaglutide | 140 | 28 |
| Sertraline Hcl | Sertraline Hcl | 128 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 32 |
| Trazodone Hcl | Trazodone Hcl | 115 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 115 | 29 |
| Bupropion Hcl Sr | Bupropion Hcl | 113 | 26 |
| Metformin Hcl Er | Metformin Hcl | 113 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 37 |
| Furosemide | Furosemide | 112 | 36 |
| Donepezil Hcl | Donepezil Hcl | 110 | 32 |
| Prednisone | Prednisone | 110 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 108 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 32 |
| Tramadol Hcl | Tramadol Hcl | 106 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 99 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 97 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 97 | 28 |
| Glimepiride | Glimepiride | 96 | 28 |
| Potassium Chloride | Potassium Chloride | 95 | 29 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 89 | 66 |
| Amitriptyline Hcl | Amitriptyline Hcl | 85 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 29 |
| Eliquis | Apixaban | 82 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 21 |
| Allopurinol | Allopurinol | 75 | 22 |
| Finasteride | Finasteride | 74 | 22 |
| Mounjaro | Tirzepatide | 73 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 22 |
| Spironolactone | Spironolactone | 67 | 19 |
| Buspirone Hcl | Buspirone Hcl | 65 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 18 |
| Atenolol | Atenolol | 61 | 19 |
| Clonazepam | Clonazepam | 61 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 17 |
| Ibuprofen | Ibuprofen | 59 | 14 |
| Simvastatin | Simvastatin | 59 | 15 |
| Famotidine | Famotidine | 52 | 15 |
| Memantine Hcl | Memantine Hcl | 50 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 19 |
| Celecoxib | Celecoxib | 45 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 12 |
| Topiramate | Topiramate | 42 | 15 |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 12 |
| Ezetimibe | Ezetimibe | 39 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 31 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 11 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 28 |
| Glipizide | Glipizide | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 30 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 26 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Belsomra | Suvorexant | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 18 |
| Diazepam | Diazepam | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Nystatin | Nystatin | 14 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Savella | Milnacipran Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $130.76 · 7 records | ABBVIE INC. | Auvelity, Dexcom G6 Transmitter, NURTEC ODT, QULIPTA, UBRELVY, XIFAXAN, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error